Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Call Transcript

Onaiza Cadoret: We’ve — yes. No, that’s great. I think we’ve done obviously some good market understanding on this as well. Just a reminder, this is a rare disease population for FCS. They really have no tools at their disposal. This is where the first-line treatment is restrictive diet and it’s just not — I mean, they just can’t continue on that level of restrictive diet that they’re on for a while. So there’s just a huge unmet need. I really do think that this is going to be — let’s get the product that’s efficacious but also really safe and easy to use. And I think getting some of the safety tolerability and here is going to be really important versus first generation, and it’s going to be a well go. A lot of lipidologist and a lot of patients are waiting.

Brett Monia : Thank you. Thanks, everybody, for joining us today for today’s call. We’re well on our way. We’re planning to continue our strong momentum in the second half of this year by delivering across all of our aspects of our business, commercial pipeline, technology and so on. Also, I want to highlight that we’re looking forward to providing a comprehensive update on all the great progress we’re making on at our Investor Day on October 4. We really hope that many of you can join in person for that meeting. I hope to see you there. Until then, thanks, and have a great day, everybody.

Operator: The conference has now concluded. Thank you for your participation. You may now disconnect your lines.